ArticleThe open cardiovascular medicine journal2011
Dyslipidaemia in rheumatological autoimmune diseases.
Article in The open cardiovascular medicine journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Dyslipidemia in Myasthenia Gravis: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Differential laboratory monitoring in autoimmune disease: a matched case-control study from Qatar primary care.Journal of translational medicine · 2026Article
- Short-, medium-, versus long-chain fatty acids: mechanisms of immunomodulation and disease pathogenesis.Cellular & molecular immunology · 2026Review
- Disease and Medication Context Shape Ex Vivo Metabolite Stability: A Pilot Study in Systemic Lupus Erythematosus.Metabolites · 2025Article
- Mediating role of basophils in the triacylglycerol-asthma link: a Mendelian randomization study.3 Biotech · 2025Article
- Efficacy and safety of abatacept in rheumatoid arthritis patients in Western region in Saudi Arabia: a multi-center study.BMC rheumatology · 2025Article
- Genetic association with autoimmune diseases identifies molecular mechanisms of coronary artery disease.iScience · 2024Article
- Article
- Review
- High-density lipoprotein cholesterol subfraction HDL2 is associated with improved endothelial function in systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy.Frontiers in molecular biosciences · 2024Review
- Lipid metabolism and rheumatoid arthritis.Frontiers in immunology · 2023Review
- Article
- Is it time to change the goals of lipid management in type 1 diabetes mellitus? Changes in apolipoprotein levels during the first year of type 1 diabetes mellitus. Prospective InLipoDiab1 study.Archives of medical science : AMS · 2022Article
- The role of high-density lipoprotein in the regulation of the immune response: implications for atherosclerosis and autoimmunity.Immunology · 2021Review
- Role of Janus Kinase Inhibitors in Therapy of Psoriasis.Journal of clinical medicine · 2021Review
- Biomarkers of lipid metabolism in patients with juvenile idiopathic arthritis: relationship with disease subtype and inflammatory activity.Pediatric rheumatology online journal · 2021Article
- Lipid Alterations in Systemic Sclerosis.Frontiers in molecular biosciences · 2021Review
- Untying the correlation between apolipoproteins and rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- The Evaluation of Serum Lipids Profile in Patients with Pemphigus Vulgaris: A Case-Control Study.The Malaysian journal of medical sciences : MJMS · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmunity forms the basis of many rheumatological diseases, and may contribute not only to the classical clinical manifestations but also to the complications. Many of the autoimmune rheumatological diseases, including rheumatoid arthritis and systemic lupus erythematosus are associated with an excess cardiovascular morbidity and mortality. Much of this excess cardiovascular risk can be attributed to atherosclerotic disease. Atherosclerosis is a complex pathological process, with dyslipidaemia and inflammation fundamental to all stages of plaque evolution. The heightened inflammatory state seen in conjunction with many rheumatological diseases may accelerate plaque formation, both through direct effects on the arterial wall and indirectly through inflammation-mediated alterations in the lipid profile. Alongside these factors, antibodies produced as part of the autoimmune nature of these conditions may lead to alterations in the lipid profile and promote atherosclerosis. In this review, we discuss the association between several of the rheumatological autoimmune diseases and dyslipidaemia, and the potential cardiovascular impact this may confer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.